The Histone Methyltransferases Market size is estimated to reach $456.7 million by 2030, growing at a CAGR of 5.3% during the forecast period 2023-2030. The growth of the Histone Methyltransferases Industry is greatly fueled by the increasing application of histone methyltransferases in the diagnosis of cancer and growing R&D activities for the development of cancer medications. These factors contribute to the Histone Methyltransferases Industry Outlook. There are principally 7 significant families of methyltransferases recognized to date. These include EZ, SET1, SET2, SMYD, SUV39, SUV4-20 and RIZ as principal families and SET8/PR-SET7 and SET7/9 as additional families. According to IndustryARC’s analysis, North America has emerged as the most profitable region in the market. In 2022, the North American region held a 37% share of the total revenue earned by the market globally, owing to rising awareness pertaining to Histone Methyltransferase in the North American region.

For More Queries About "Histone Methyltransferases Market" @

Histone Methyltransferases Market Growth Drivers:

  • Rising Applications of SMYD3:

Histone Methyltransferases (HMT) are histone-modifying enzymes that mobilize the transfer of one, two or three methyl groups to lysine and arginine residues of histone proteins. Based on type, the Histone Methyltransferases Market is segmented into EZ, SET1, SET2, SMYD, SUV39, SUV4-20 and RIZ. The recognition of SMYD3 has been recorded and it is a gene that is over-expressed in most colorectal carcinomas and hepatocellular carcinomas. The establishment of SMYD3 into NIH3T3 cells improves cell development, whereas genetic knockdown with small-interfering RNAs (siRNAs) in cancer cells led to considerable growth suppression. SMYD3 produced a complex with RNA polymerase II by way of interaction with the RNA helicase HELZ and transactivated a set of genes that involved oncogenes, homeobox genes and genes connected with cell-cycle regulation. The rising applications of SMYD3 are therefore driving the growth of the Histone Methyltransferases Market.

  • Inhibitory Impacts of SUV4-20 H1 Histone Methyltransferase:

EZ, SET1, SET2, SMYD, SUV39, SUV4-20 and RIZ are recognized as principal families of Histone Methyltransferases. It has been recognized that SUV4-20 histone methyltransferases, particularly SUV4-20 H1, serve a significant role in the regulation of FXN expression and depict a novel therapeutic target. It has been discovered that pharmacological inhibition of the SUV4-20 methyltransferases by the tool compound A-196 raised the expression of FXN by approximately 1.5-fold in the reporter cell line. The inhibitory impacts of SUV4-20 H1 Histone Methyltransferase are therefore propelling the growth of the Histone Methyltransferases Industry, thereby contributing to the growth of the Histone Methyltransferases Industry Outlook.


In September 2021, Boehringer Ingelheim declared the acquisition of Abexxa Biologics Inc. The acquisition would permit Boehringer Ingelheim to access Abexxa’s expertise in targeting cancer-specific proteins. These proteins are situated within the cell, instead of those expressed on the cell membrane.

Histone Methyltransferases Market: Competitive Landscape

The key companies holding major shares in the Histone Methyltransferases Market are Diagenode, a Hologic company, Cell Signaling Technology, Inc., Cayman Chemical Company, Boehringer Ingelheim group, Bellbrook Labs, Constellation Pharmaceuticals, CELLCENTRIC LIMITED, Domainex, Sequenom, Inc. and Ribomed Biotechnologies, Inc.

To request for a quote, provide your details in the below link:

Media Contact:

Mr. Venkat Reddy
Sales Manager
Contact Sales: +1-970-236-3677

About IndustryARC: IndustryARC is a Research and Consulting Firm that publishes more than 500 reports annually, in various industries such as Agriculture, Automotive, Automation & Instrumentation, Chemicals and Materials, Energy and Power, Electronics, Food and Beverages, Information Technology, and Life sciences and Healthcare.